Description

AI as a tool offers many benefits to the life sciences industry but it is not without challenges. With the introduction of the EU's AI Act and the US and EU signing an agreement of collaboration regarding the regulation of AI, it is imperative that QARA departments are able to guide their companies to adhere to standards. Since healthcare data is all high-risk data, companies must be able to recognize and mitigate potential biases and risks in addition to being transparent with acceptable risks. Besides data accuracy risks, accessibility and security all must be discussed as the industry evolves. Join us as we discuss the evolution of AI’s role for QARA from different perspectives in the industry.

Register Now